Alps Advisors Inc Rigel Pharmaceuticals Inc Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $8,494 - $94,208	-7,722 Reduced 7.57%	94,343 $111,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $49,836 - $237,281	-74,383 Reduced 42.16%	102,065 $115,000
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $47,632 - $74,023	-21,456 Reduced 10.84%	176,448 $528,000
Q4 2021 Feb 09, 2022	BUY	$2.36 - $3.57 $467,053 - $706,517	197,904 New	197,904 $524,000
Q4 2020 Feb 03, 2021	SELL	$2.35 - $3.74 $506,269 - $805,723	-215,434 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$1.78 - $4.13 $25,863 - $60,008	-14,530 Reduced 6.32%	215,434 $517,000
Q2 2020 Aug 05, 2020	SELL	$1.41 - $2.05 $105,413 - $153,260	-74,761 Reduced 24.53%	229,964 $421,000
Q1 2020 May 06, 2020	SELL	$1.27 - $3.0 $45,123 - $106,590	-35,530 Reduced 10.44%	304,725 $475,000
Q4 2019 Feb 07, 2020	BUY	$1.6 - $2.43 $9,614 - $14,601	6,009 Added 1.8%	340,255 $728,000
Q3 2019 Nov 04, 2019	SELL	$1.63 - $2.62 $25,597 - $41,144	-15,704 Reduced 4.49%	334,246 $625,000
Q2 2019 Aug 07, 2019	BUY	$2.02 - $2.61 $706,899 - $913,369	349,950 New	349,950 $913,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.